Eris Lifesciences is currently trading at Rs. 1382.95, up by 31.60 points or 2.34% from its previous closing of Rs. 1351.35 on the BSE.

The scrip opened at Rs. 1350.00 and has touched a high and low of Rs. 1402.00 and Rs. 1350.00 respectively. So far 3349 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1909.55 on 12-Jun-2025 and a 52 week low of Rs. 1140.00 on 03-Mar-2025.

Last one week high and low of the scrip stood at Rs. 1402.00 and Rs. 1315.05 respectively. The current market cap of the company is Rs. 19157.07 crore.

The promoters holding in the company stood at 54.85%, while Institutions and Non-Institutions held 27.17% and 17.99% respectively.

Eris Lifesciences has entered into strategic partnership with Natco Pharma for the commercialisation of Semaglutide in India, reinforcing Eris’s commitment to expanding its leadership in the fast-growing diabetes and metabolic care segment.

Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management driven by robust clinical outcomes in glycemic control and weight reduction. With India witnessing a rapidly growing diabetic population and increasing awareness around obesity management, GLP-1 therapies represent a high-growth opportunity within the metabolic segment.

Eris has built a strong and scalable presence in diabetology over the years, supported by a wide specialist reach and deep engagement with endocrinologists, diabetologists and physicians across India. The addition of semaglutide is expected to further strengthen Eris’ portfolio in advanced diabetes therapies and enhance its participation in next-generation metabolic treatments. This collaboration builds on both companies’ complementary strengths: Eris’s robust commercial and diabetes franchise presence, and Natco’s manufacturing and regulatory prowess in complex formulations. 

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.